Studies have shown that the aberrant expression of RGS2 is associated with the tumorigenesis of breast cancer, prostate cancer, ovarian cancer, lymphoma and acute myeloid leukemia [35]. This evidence concerns the gene RGS2 and prostate carcinoma.